Antithrombotic Treatment of Embolic Stroke of Undetermined SourceHans‐Christoph Diener, Wolf-Rüdiger Schäbitz, Ralph L. Sacco et al.|Stroke|2020Cited by 34
#1418 Phase II dose-selection, randomised, controlled trial of ASi BI 690517 with and without EMPA in CKD: subgroup analysis by T2D statusDick de Zeeuw, Peter Rossing, Sibylle J. Hauske et al.|Nephrology Dialysis Transplantation|2024Cited by 1
Cumulative Effects of Aldosterone Synthase and SGLT2 Inhibition on Albuminuria in People with CKDPeter Rossing, Katherine R. Tuttle, Sibylle J. Hauske et al.|Journal of the American Society of Nephrology|2024Cited by 1
WCN25-2620 CUMULATIVE EFFECTS OF THE ALDOSTERONE SYNTHASE INHIBITOR VICADROSTAT COMBINED WITH EMPAGLIFLOZIN ON ALBUMINURIA IN PEOPLE WITH CKDPeter Rossing, Katherine R. Tuttle, Dick de Zeeuw et al.|Kidney International Reports|2025Cited by 1
Cumulative Effects of Vicadrostat (BI 690517) and Empagliflozin on Albuminuria in People with Chronic Kidney DiseasePeter Rossing, Katherine R. Tuttle, Sibylle J. Hauske et al.|Metabolism|2025Cited by 0